Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | NPC1 | O15118 | 3/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4920918 | 0.83 | RAB9A (0.80) | KMT2AMEN1CYP2C9RAB9ANPC1 | |
| SCHEMBL31665238 | 0.81 | SMN1; SMN2 (0.54) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| SCHEMBL25142386 | 0.80 | RAB9A (0.65) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| SCHEMBL25142484 | 0.80 | RAB9A (0.65) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| SCHEMBL31665255 | 0.79 | SMN1; SMN2 (0.52) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| SCHEMBL25142998 | 0.79 | RAB9A (0.64) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| SCHEMBL25143148 | 0.79 | RAB9A (0.64) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| SCHEMBL31110158 | 0.78 | RAB9A (0.65) | KMT2AMEN1CYP2C9RAB9ANPC1 | |
| SCHEMBL31665243 | 0.78 | MAPT (0.52) | KMT2AMEN1RAB9ANPC1RXFP1 | |
| Bromide SCHEMBL27908125 | 0.77 | HPGD (0.69) | KMT2AMEN1CYP2C9RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | KMT2A 2300/4885MEN1 2854/4885CYP2C9 2985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.